0000950123-21-007771 Sample Contracts

CONFIDENTIAL

Exclusive License Agreement • June 11th, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • California

• Contract Type
  Exclusive License Agreement
• Filed
  June 11th, 2021
• Company
  Caribou Biosciences, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  California

This license agreement (“Agreement”), effective as of the date of the last signature below (“Effective Date”), is entered into by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 acting through its Office of Technology Licensing, at the University of California, Berkeley, having its administrative office at 2150 Shattuck Avenue, Suite 510, Berkeley, California 94720-1620 (“REGENTS”), The University of Vienna, having a business address at Universltatsring 1, 1010, Vienna, Austria acting through its Research Services and Career Development Office; University of Berggasse 7, 2nd floor 1090 Vienna, Austria (“UNIVERSITY OF VIENNA”) and Caribou Biosciences, Inc., a Delaware corporation, having a principal place of business at QB3 Garage, MS#3220, Stanley Hall, Rm. 130, Berkeley, California 94720 (“LICENSEE”). REGENTS and UNIVERSITY OF VIENNA shall

Amendment No. 3 to Exclusive License Agreement for Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription

Caribou Biosciences, Inc. • June 11th, 2021 • Biological products, (no disgnostic substances)

• Company
  Caribou Biosciences, Inc.
• Filed
  June 11th, 2021
• Industry
  Biological products, (no disgnostic substances)

This Amendment No. 3 is made to the Exclusive License Agreement for Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription, dated April 16, 2013, as amended by an Amendment Agreement, dated April 17, 2013, and as further amended by Amendment No. 2 to Exclusive License Agreement for Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription, dated March 14, 2019, and as clarified in the Memorandum of Understanding, dated March 14, 2019 (collectively, the “License Agreement”), by and among The Regents of the University of California, the University of Vienna, and Caribou Biosciences, Inc., and is effective April 16, 2021 (the “Amendment Effective Date”). Caribou Biosciences, Inc. is referred to as “LICENSEE” and The Regents of the University of California (“REGENTS”) and the University of Vienna are collectively referred to as “LICENSORS.” Capitalized terms not defined here